Intestifalk

Budesonide, the active ingredient in Intestifalk, is a glucocorticoid presented as an oral formulation for oral use. It treats inflammatory bowel diseases such as Crohn's disease and ulcerative colitis in adult patients.

GNH USA supplies Intestifalk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intestifalk, a glucocorticoid, is used to manage inflammatory conditions of the gastrointestinal tract.

- Crohn's disease: reduces intestinal inflammation and helps achieve remission. - Ulcerative colitis: controls colonic inflammation and maintains disease remission. - Inflammatory bowel disease (IBD): provides targeted anti‑inflammatory effect throughout the gut.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Abdominal pain: mild discomfort. - Oral thrush: fungal overgrowth in the mouth. - Increased appetite: may lead to weight gain. - Mild insomnia: difficulty falling asleep.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Severe infection: opportunistic bacterial or fungal infections. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Perforated ulcer: rare gastrointestinal perforation. - Severe hyperglycemia: marked elevation of blood glucose. - Osteoporosis: decreased bone mineral density with long‑term use.

Before initiating therapy, consider the following precautions: - Monitor adrenal function: assess cortisol levels during prolonged treatment. - Assess for infection: avoid use in active systemic infections. - Evaluate bone health: consider calcium and vitamin D supplementation. - Use with caution in diabetics: monitor blood glucose closely. - Avoid abrupt discontinuation: taper dose to prevent withdrawal. - Store at ambient temperature: keep in the original pack, protect from moisture.

Budesonide may interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition increases budesonide exposure. - Itraconazole: potent CYP3A4 inhibitor, may raise systemic levels. - Ritonavir: enhances budesonide concentrations via CYP3A4 blockade.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant effect, monitor INR. - Insulin or oral hypoglycemics: glucocorticoid effect can affect glucose control. - NSAIDs: combined use may increase gastrointestinal irritation.